Ascendiant Capital Markets Weighs in on Aclarion Q2 Earnings

Aclarion, Inc. (NASDAQ:ACON) – Research analysts at Ascendiant Capital Markets cut their Q2 2026 EPS estimates for Aclarion in a note issued to investors on Thursday, May 28th. Ascendiant Capital Markets analyst L. Ward now forecasts that the company will post earnings per share of ($1.05) for the quarter, down from their previous forecast of ($0.95). Ascendiant Capital Markets currently has a “Buy” rating and a $7.50 price target on the stock. The consensus estimate for Aclarion’s current full-year earnings is ($4.37) per share. Ascendiant Capital Markets also issued estimates for Aclarion’s Q3 2026 earnings at ($1.05) EPS and FY2026 earnings at ($4.51) EPS.

Aclarion (NASDAQ:ACON) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($1.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.55) by $0.21. Aclarion had a negative net margin of 10,320.51% and a negative return on equity of 54.41%. The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.03 million.

ACON has been the subject of a number of other research reports. Weiss Ratings raised shares of Aclarion from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, May 22nd. Wall Street Zen raised shares of Aclarion from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $7.50.

Aclarion Stock Performance

ACON opened at $3.50 on Thursday. Aclarion has a fifty-two week low of $2.34 and a fifty-two week high of $12.03. The company has a fifty day moving average of $3.31 and a two-hundred day moving average of $4.02. The stock has a market capitalization of $8.61 million, a price-to-earnings ratio of -0.39 and a beta of 1.22.

Aclarion announced that its board has approved a share repurchase program on Wednesday, April 22nd that authorizes the company to buyback $2.50 million in shares. This buyback authorization authorizes the company to reacquire up to 31% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s leadership believes its shares are undervalued.

Key Aclarion News

Here are the key news stories impacting Aclarion this week:

• Positive Sentiment: Aclarion expanded Nociscan’s reach by partnering with the Institute of Neuro Innovation in Los Angeles, which could increase clinical usage and improve the company’s commercialization prospects. Article Title
• Positive Sentiment: The collaboration is designed to build real-world evidence for Nociscan, which may strengthen adoption among physicians, payers, and providers over time. Article Title
• Neutral Sentiment: Ascendiant Capital Markets kept a Buy rating and $7.50 target, but trimmed near-term and FY2026 EPS estimates, signaling ongoing losses even as it remains constructive on the stock. Article Title
• Negative Sentiment: Analysts’ lowered EPS forecasts for Q2 2026, Q3 2026, and FY2026 highlight that Aclarion is still expected to post meaningful losses, which can temper enthusiasm. Article Title

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.